HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

Abstract
Tumor-infiltrating myeloid cells (TIMs) support tumor growth by promoting angiogenesis and suppressing antitumor immune responses. CSF-1 receptor (CSF1R) signaling is important for the recruitment of CD11b(+)F4/80(+) tumor-associated macrophages (TAMs) and contributes to myeloid cell-mediated angiogenesis. However, the impact of the CSF1R signaling pathway on other TIM subsets, including CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSCs), is unknown. Tumor-infiltrating MDSCs have also been shown to contribute to tumor angiogenesis and have recently been implicated in tumor resistance to antiangiogenic therapy, yet their precise involvement in these processes is not well understood. Here, we use the selective pharmacologic inhibitor of CSF1R signaling, GW2580, to demonstrate that CSF-1 regulates the tumor recruitment of CD11b(+)Gr-1(lo)Ly6C(hi) mononuclear MDSCs. Targeting these TIM subsets inhibits tumor angiogenesis associated with reduced expression of proangiogenic and immunosuppressive genes. Combination therapy using GW2580 with an anti-VEGFR-2 antibody synergistically suppresses tumor growth and severely impairs tumor angiogenesis along with reverting at least one TIM-mediated antiangiogenic compensatory mechanism involving MMP-9. These data highlight the importance of CSF1R signaling in the recruitment and function of distinct TIM subsets, including MDSCs, and validate the benefits of targeting CSF1R signaling in combination with antiangiogenic drugs for the treatment of solid cancers.
AuthorsSaul J Priceman, James L Sung, Zory Shaposhnik, Jeremy B Burton, Antoni X Torres-Collado, Diana L Moughon, Mai Johnson, Aldons J Lusis, Donald A Cohen, M Luisa Iruela-Arispe, Lily Wu
JournalBlood (Blood) Vol. 115 Issue 7 Pg. 1461-71 (Feb 18 2010) ISSN: 1528-0020 [Electronic] United States
PMID20008303 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine
  • Anisoles
  • Pyrimidines
  • Receptor, Macrophage Colony-Stimulating Factor
  • Vascular Endothelial Growth Factor Receptor-2
  • Matrix Metalloproteinase 9
Topics
  • Animals
  • Anisoles (pharmacology)
  • Carcinoma, Lewis Lung (drug therapy, pathology)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Lung Neoplasms (drug therapy, pathology)
  • Macrophages (cytology)
  • Male
  • Matrix Metalloproteinase 9 (metabolism)
  • Melanoma (drug therapy, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Myeloid Cells (drug effects, pathology)
  • Neoplasm Transplantation
  • Neovascularization, Pathologic (drug therapy, metabolism)
  • Prostatic Neoplasms (drug therapy, pathology)
  • Pyrimidines (pharmacology)
  • Rats
  • Receptor, Macrophage Colony-Stimulating Factor (antagonists & inhibitors, metabolism)
  • Signal Transduction (drug effects)
  • Skin Neoplasms (drug therapy, pathology)
  • Vascular Endothelial Growth Factor Receptor-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: